About Flame Biosciences
Flame Biosciences is a company based in New York (United States) founded in 2019 by Charles J Fisher and Bob Stein.. Flame Biosciences has raised $108.52 million across 2 funding rounds. Flame Biosciences operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter New York, United States
- Founders Charles J Fisher, Bob Stein
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$108.52 M (USD)
in 2 rounds
-
Latest Funding Round
$100 M (USD), Series B
Sep 30, 2020
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Flame Biosciences
Flame Biosciences has successfully raised a total of $108.52M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $100 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $100.0M
-
First Round
First Round
(16 Mar 2020)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2020 | Amount | Series B - Flame Biosciences | Valuation |
investors |
|
| Mar, 2020 | Amount | Series A - Flame Biosciences | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Flame Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Flame Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Flame Biosciences Comparisons
Competitors of Flame Biosciences
Flame Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| domain | founded_year | HQ Location |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for allergic and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Flame Biosciences
Frequently Asked Questions about Flame Biosciences
When was Flame Biosciences founded?
Flame Biosciences was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Where is Flame Biosciences located?
Flame Biosciences is headquartered in New York, United States. It is registered at New York, New York, United States.
Who is the current CEO of Flame Biosciences?
Harlan Weisman is the current CEO of Flame Biosciences.
Is Flame Biosciences a funded company?
Flame Biosciences is a funded company, having raised a total of $108.52M across 2 funding rounds to date. The company's 1st funding round was a Series A of $8.52M, raised on Mar 16, 2020.
What does Flame Biosciences do?
Flame Biosciences was founded in 2019 and is based in New York, United States. Operations center on the biotechnology sector, where drugs targeting cancer and inflammatory conditions are developed and manufactured. The pipeline addresses chronic inflammation-related issues, including lung cancers and chronic kidney disease. FL-101 is pursued for treating inflammation-associated lung cancers, while FL-201 is designed to alleviate chronic inflammation in patients with severe conditions.
Who are the top competitors of Flame Biosciences?
Flame Biosciences's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.